Cronin C M, Sallan S E, Wolfe L
Pharmacotherapy. 1982 Jan-Feb;2(1):29-31. doi: 10.1002/j.1875-9114.1982.tb03169.x.
Motion sickness is a common clinical malady. Until recently, the use of scopolamine, the drug of choice for the treatment of motion-induced nausea and vomiting, has been sometimes associated with a variety of unacceptable side effects. These side effects could result from the unpredictable blood levels attained with oral dosage (pulse delivery). A new system of drug delivery, the transdermal therapeutic system (TTS)--Transderm-V--has been developed. The TTS delivers scopolamine across the skin at a constant rate. This permits a drug with a very short half life to be administered over prolonged periods, thereby maintaining blood concentrations at the defined therapeutic level. This precludes the necessity for frequent dosing and increases patient acceptability and compliance while minimizing the untoward effects associated with conventional dosage forms of the drug.
晕动病是一种常见的临床病症。直到最近，东莨菪碱作为治疗晕动病引起的恶心和呕吐的首选药物，有时会伴有各种难以接受的副作用。这些副作用可能源于口服给药（脉冲式给药）所达到的不可预测的血药浓度。一种新的给药系统——经皮治疗系统（TTS）——Transderm-V已经研发出来。经皮治疗系统能以恒定速率使东莨菪碱透过皮肤。这使得半衰期很短的药物能够长时间给药，从而将血药浓度维持在规定的治疗水平。这就避免了频繁给药的必要性，提高了患者的接受度和依从性，同时将与该药物传统剂型相关的不良影响降至最低。
